Abstract

Malaria remained a global health crisis, with increasing resistance to conventional antimalarials including 
chloroquine and artemisinin derivatives, threatening disease control efforts. Ferroquine, a ferrocene-containing 
derivative of chloroquine, represents an innovative organometallic approach to antimalarial drug development 
designed to overcome resistance mechanisms while maintaining efficacy against chloroquine-resistant Plasmodium 
falciparum strains. This review evaluated the pharmacological properties of ferroquine, examined its activity against 
resistant parasite strains, assessed clinical development progress, and analyzed its potential role in future malaria 
treatment strategies. A comprehensive literature search of peer-reviewed journals, clinical trial registries, and 
regulatory documents published between 2010 and 2025 was conducted, focusing on ferroquine pharmacology, 
mechanism of action, resistance profiles, preclinical studies, and clinical trial outcomes. Ferroquine demonstrated 
potent activity against chloroquine-resistant and multidrug-resistant Plasmodium strains through mechanisms 
involving enhanced lipophilicity, altered accumulation kinetics, and potential redox-mediated parasite toxicity. 
Pharmacokinetic studies revealed extended half-life and favorable tissue distribution compared to parent chloroquine 
compound. Phase II clinical trials combining ferroquine with artesunate showed excellent efficacy and safety profiles, 
achieving cure rates exceeding 95 percent in African populations. However, phase III development encountered 
regulatory challenges, and the compound has not yet achieved market approval despite promising clinical data. 
Resistance development appears slower than with conventional quinolines, though specific resistance markers 
require further characterization. Ferroquine represented a scientifically innovative antimalarial with substantial 
clinical potential, yet translational challenges highlight the complex pathway from molecular innovation to 
therapeutic deployment in resource-limited endemic settings.